Contact Us

Mailing Address: 27 West Morten Avenue, Phoenix, AZ 85021-7246
Phone: (602) 618-0183 | Fax: (602) 926-8109 |

By appointment at our Phoenix or Scottsdale offices: 
Phone: (602) 618-0183 or 

ICAN®, International Cancer Advocacy Network is a 501(c)(3) nonprofit organization.

ICAN's Strict "NO Telemarketing" Policy

ICAN does not engage in or contract with others for telemarketing to solicit donations.

Beware of Fraudulent Phone Solicitations!

ICAN never engages in or contracts anyone to place solicitation calls or mass mailings. If you are called for a donation, it's likely NOT a call from us.

As you know, there are many scam artists who seek to take advantage of people's generosity and they solicit funds claiming that it is going to a good cause (disaster relief, cancer, etc.). Always verify who you are speaking to and whether the solicitation is legitimate. ICAN does not engage in telephone solicitations and has never done any telemarketing or solicitation of funds by phone since our founding more than 25 years ago. If you are receiving any calls from an organization calling itself "ICAN," and the caller is telling you that it is a cancer organization, you are being called by a fraudster and not by us. There are many organizations worldwide, including very legitimate ones, that use the acronym ICAN. There is, however, only one ICAN, International Cancer Advocacy Network.

Please note down any information regarding a suspicious caller (phone number, web address, physical address, etc.) and report it to the appropriate authorities or to us.

Please also see our Privacy Statement

If you are contacting ICAN with regard to a matter UNRELATED to our Patient Services, please call 602-618-0183 or email If you have not heard back within 48 hours, call us at 602-618-0183 or email us at

For questions, problems or suggestions about this website, please contact the webmaster.

ICAN 10-Point Patient Accrual and Screening Process

  1. The patient directly contacts ICAN. The organization may conditionally accept the case, informing the patient that ICAN maintains Wait List status for its oversubscribed Personalized Medicine Programs. During Wait List periods on a per-Program basis, ICAN accepts the most critically ill patients first and/or those patients at key turning points in their battles for life (e.g. having to make a decision on entry into a clinical trial, etc.) where time is of the essence.
  2. While ICAN often works directly with the patient’s spouse or other family member, the patient must give ICAN full consent before ICAN takes on the role as his/her patient advocate.
  3. The patient provides 100 percent of the medical record to ICAN, with all updates and agrees to an intake telephone interview (time varies according to issues involved but may last up to two hours). ICAN advises each patient, based on the issues involved, how to maintain ICAN’s “Patient Binder” going forward to collect all medical records.
  4. The patient consults with his medical team as to any ICAN recommendation and understands that ICAN staff and volunteers dispense robust patient advocacy and do not practice medicine. The patient agrees that no member of ICAN’s professional councils receives identifying information about any ICAN patient. All issues that come before members of ICAN’s professional councils are handled on an de-identified basis.
  5. The patient consents in advance and makes arrangements that ICAN is to receive copies of all additions to the patient’s medical record, including all molecular profiling, sequencing, functional profiling, and chemosensitivity/ chemoresistance reports. The patient understands that while ICAN maintains a Physicians Advisory Council, a Biomarkers Council, a Scientific Advisory Council, and other professional councils, it is solely the province of ICAN professional advocacy staff to determine which cases are reviewed (on an de-identified basis) by any member or members of such councils. The patient further understands that ICAN is independent of all entities in the global oncology space and that the patient, were he or she to consent to tissue banking, for example, would be directed to the external governing body that would oversee the execution of formal informed consents to transfer the patient’s tissue.
  6. The patient understands that ICAN does not handle reimbursement issues, financing issues, insurance, or disability appeals, but refers such issues to other organizations.
  7. For international cases, ICAN will use its best efforts to provide translation of our advocacy recommendations into the patient’s language.
  8. The patient understands that ICAN professional advocacy staff and key Research Services and Patient Services volunteers comply with HIPAA at all times, and that ICAN will never release any facts concerning the patient’s case to any third party or to anyone at ICAN who is not directly involved with the patient’s case. The patient thus specifically agrees that ICAN is to disclose no details about the patient’s case to any third party beyond ICAN’s designated professional patient advocate(s) without the patient’s express written consent.
  9. For document control purposes and in conjunction with the organization’s Patient Privacy and Medical Records Destruction Policy, ICAN continuously shreds patient records.
  10. The patient is informed from the beginning of his or her case that ICAN has had a long-standing policy not to solicit funds from patients or to involve patients in fund solicitation without express “opt-in” consent. Spontaneous contributions, tribute donations, and event attendance and/or event sponsorships are, however, gratefully accepted by the organization, as are spontaneous and detailed testimonials.

For further information, please email or call 602-618-0183.


All ICAN operations and Patient Advocacy Programs are in strict compliance with HIPAA; HIPAA Security Rules; the Gramm, Leach, Bliley Safeguard Rule; and the Fair and Accurate Credit Transaction Act.

Please do not mail or fax patient information that contains Social Security Numbers or Dates of Birth without thoroughly blacking out such confidential information first. We zealously protect our patient's privacy at ICAN.

Please refer to the following policies:
Privacy Statement
Medical Information Policy
Patient Privacy Policy Pursuant to HIPAA
Funding, Sponsors, Advertisers
No Telemarketing Policy

Guidestar Platinum Seal of Transparency 2021

Federal Tax I.D.: EIN 86-0818253

This website provides information about ICAN's Personalized Medicine Cancer Case Navigation Programs, while it also describes ICAN's multi-faceted mission, unique vision, and respected values. Intended for use by the general public. This site also offers more in-depth information for target populations who may benefit from ICAN's Program Services such as ICAN patients, their caregivers and medical teams — along with those healthcare professionals and researchers who are involved with ICAN's medical and scientific councils.

The health news displayed on this site are chosen by our team of M.D.s, PhDs, and ICAN's President and CEO, who is an Affiliate Member of ASCO, the American Society of Clinical Oncology; AMP, the Association for Molecular Pathology; and AACR, the American Association for Cancer Research.

Information contained herein is therefore not intended to substitute for or supersede any advice that a patient receives from his/her health professional and is not intended to compromise in any way the patient-physician relationship. ICAN strongly believes that all medical decisions need to be made, via shared decision-making, by the patient and his/her medical team.